<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310648</url>
  </required_header>
  <id_info>
    <org_study_id>M70P1</org_study_id>
    <secondary_id>Part 1: 200511-I</secondary_id>
    <secondary_id>Part 2: 200511-III</secondary_id>
    <nct_id>NCT00310648</nct_id>
  </id_info>
  <brief_title>Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (&gt; 60 Years)</brief_title>
  <official_title>Part 1:Phase I Open-Label, Single-Center to Evaluate the Safety of a Commercially Available Adjuvanted Influenza Vaccine When Administered to Elderly Subjects Part 2: A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Immunogenicity and Safety of a Commercially Available Influenza Vaccine and a Conventional Commercially Available Influenza Vaccine When Administered to Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiron s.r.l. Beijing Representative Office</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Clinical Trial in Two parts:

      Part 1: Phase I, Open-Label, Single-Center Study to Evaluate the Safety of an adjuvanted
      Influenza Vaccine When Administered to Elderly Subjects.

      Part 2: A Phase III, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate
      the Immunogenicity and Safety of an adjuvanted and a conventional Influenza Vaccine When
      Administered to Elderly Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Requirements For Drug Registration &amp; Guide Principles For ClinicaL Trial Techniques of Vaccine e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited Local and Systemic Reactions Within 6 Days Following Vaccination And Adverse Events Thought the Study.</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 60 years of age or older, mentally competent, willing and able to give the
             written informed consent prior to study entry

        Exclusion Criteria:

          -  Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic
             disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD)
             that requires oxygen therapy, acute or progressive hepatic disease, acute or
             progressive renal disease, congestive heart failure.

          -  Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the vaccine.

          -  History of neurological symptoms or signs, or anaphylactic shock following
             administration of any vaccine.

          -  Known or suspected (or have a high risk of developing) impairment/alteration of immune
             function (excluding that normally associated with advanced age).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines - Drug Information Services</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanning</name>
      <address>
        <city>Guangxi</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>Influenza, elderly, vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

